Brokerages Set Merus N.V. (NASDAQ:MRUS) Price Target at $90.54

Merus N.V. (NASDAQ:MRUS) has been assigned a consensus rating of “Hold” from the eighteen ratings firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, thirteen have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $93.1176.

A number of equities research analysts recently weighed in on MRUS shares. Alliance Global Partners started coverage on shares of Merus in a report on Monday, August 25th. They set a “buy” rating and a $90.00 price target for the company. Needham & Company LLC downgraded shares of Merus from a “buy” rating to a “hold” rating and set a $96.00 price objective on the stock. in a research note on Monday, September 29th. Citigroup downgraded shares of Merus from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $101.00 to $97.00 in a research note on Monday, September 29th. Wells Fargo & Company restated an “equal weight” rating and issued a $97.00 price target (up from $95.00) on shares of Merus in a research report on Monday, September 29th. Finally, Wall Street Zen downgraded shares of Merus from a “hold” rating to a “sell” rating in a research report on Sunday, July 20th.

Insider Activity

In other news, COO Peter B. Silverman sold 25,000 shares of the firm’s stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $60.00, for a total value of $1,500,000.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 48,500 shares of company stock valued at $2,792,500. Company insiders own 3.70% of the company’s stock.

Institutional Trading of Merus

A number of large investors have recently modified their holdings of MRUS. Squarepoint Ops LLC acquired a new stake in shares of Merus in the 4th quarter worth about $817,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Merus by 17.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 98,744 shares of the biotechnology company’s stock worth $4,152,000 after acquiring an additional 14,544 shares during the period. California State Teachers Retirement System increased its holdings in shares of Merus by 7.5% in the 4th quarter. California State Teachers Retirement System now owns 41,149 shares of the biotechnology company’s stock worth $1,730,000 after acquiring an additional 2,872 shares during the period. GAMMA Investing LLC increased its holdings in shares of Merus by 2,153.6% during the first quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 603 shares during the period. Finally, Harbor Capital Advisors Inc. raised its stake in shares of Merus by 49.0% during the first quarter. Harbor Capital Advisors Inc. now owns 64,374 shares of the biotechnology company’s stock valued at $2,710,000 after purchasing an additional 21,166 shares in the last quarter. Institutional investors and hedge funds own 96.14% of the company’s stock.

Merus Stock Performance

Merus stock opened at $94.29 on Monday. Merus has a 1 year low of $33.19 and a 1 year high of $94.56. The firm has a 50 day moving average price of $69.49 and a 200 day moving average price of $56.16. The company has a market cap of $7.13 billion, a price-to-earnings ratio of -17.14 and a beta of 1.26.

Merus (NASDAQ:MRUS) last released its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($2.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($1.06). Merus had a negative return on equity of 50.28% and a negative net margin of 685.64%.The business had revenue of $8.83 million during the quarter, compared to analyst estimates of $9.77 million. Sell-side analysts predict that Merus will post -3.85 EPS for the current year.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.